JINYU(SH:600201)2022-04-21 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥341,659,620.42, representing a decrease of 34.22% compared to the same period last year[6] - The net profit attributable to shareholders of the listed company was ¥80,972,815.44, down 61.68% year-on-year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥89,728,564.90, a decrease of 56.73% compared to the previous year[6] - Basic earnings per share were ¥0.07, down 63.16% from the same period last year[6] - Total operating revenue for Q1 2022 was $341.66 million, a decrease of 34.2% compared to $519.42 million in Q1 2021[34] - Net profit for Q1 2022 was $84.01 million, a decline of 61.4% from $217.20 million in Q1 2021[36] - Earnings per share for Q1 2022 were $0.07, compared to $0.19 in Q1 2021[36] Cash Flow - The net cash flow from operating activities was -¥21,635,444.45, reflecting a decline of 179.93% year-on-year[6] - Cash inflow from operating activities for Q1 2022 was $252.27 million, down 30% from $360.86 million in Q1 2021[40] - Net cash outflow from operating activities was -$21.64 million, compared to a positive cash flow of $27.07 million in the same period last year[40] - Cash inflow from investment activities totaled $121.04 million, significantly up from $71.89 million in Q1 2021[41] - Net cash flow from investment activities was $76.68 million, a turnaround from a net outflow of -$111.40 million in Q1 2021[41] - Cash inflow from financing activities was $10 million, with net cash flow from financing activities at $9.96 million[42] - The ending cash and cash equivalents balance for Q1 2022 was $1.25 billion, an increase from $1.24 billion at the end of Q1 2021[42] - The company reported a cash inflow of $20 million from investment recoveries[41] - The company’s cash and cash equivalents increased by $65 million in Q1 2022, contrasting with a decrease of $84.31 million in Q1 2021[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,716,016,378.95, an increase of 1.70% from the end of the previous year[9] - The equity attributable to shareholders of the listed company was ¥5,353,343,185.78, up 1.54% compared to the end of the previous year[9] - Total liabilities increased to $1.07 billion in the latest report from $1.04 billion previously, reflecting a growth of 2.9%[30] - The company’s total liabilities included short-term borrowings of CNY 10,000,000.00, with accounts payable increasing to CNY 386,935,839.24 from CNY 341,808,778.76, a rise of approximately 13.2%[28] - The company’s non-current assets totaled CNY 3,787,249,606.27, down from CNY 3,843,285,602.38, indicating a decrease of about 1.5%[28] Operational Highlights - The decline in operating revenue was primarily due to significant losses in the pig farming industry and a decrease in the number of breeding sows[12] - The company reported non-recurring gains and losses amounting to -¥8,062,981.85, impacting overall profitability[9] - The company’s inventory stood at CNY 331,923,400.66, compared to CNY 317,652,974.28, marking an increase of about 4.5%[24] - The company’s long-term equity investments were valued at CNY 267,952,528.18, slightly down from CNY 268,301,516.68[28] - The company’s other receivables increased to CNY 72,627,196.78 from CNY 37,834,728.18, reflecting a significant growth of approximately 92%[24] Research and Community Engagement - The company’s subsidiary, Jinyu Baoling Biological Pharmaceutical Co., Ltd., received a new veterinary drug registration certificate for a Brucella vaccine, currently advancing product approval processes[21] - The company donated a mobile PCR laboratory valued at CNY 3.06 million and cash donations of CNY 7 million to support epidemic prevention efforts[21]